Pharmaxis CEO sells shares a day ahead of meltdown

A European regulatory group informally turned thumbs down on Pharmaxis's lead drug, triggering a staggering 74 percent drop in the Australian biotech's share price. And the Sydney Morning Herald follows up with the intriguing addendum that Pharmaxis CEO Alan Robertson sold 500,000 shares of company stock the day ahead of the vote. Robertson says he had a tax bill to pay. Pharmaxis has been seeking approval to sell Bronchitol for cystic fibrosis. Report

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.